Phycomycosis: Fungal Infections by Lower Fungi

Phycomycosis represents a group of serious fungal infections caused by lower fungi, organisms that typically exist harmlessly in our environment but can turn deadly when they invade human tissues. Understanding this condition is crucial for healthcare professionals and nursing students, particularly when caring for vulnerable patient populations.

What is phycomycosis? 🔗

Phycomycosis is a term used to describe infections caused by fungi belonging to the class Zygomycetes. The condition is also known as zygomycosis or mucormycosis, with these terms often used interchangeably in medical literature. These infections are caused by common environmental molds that most people encounter daily without any harmful effects.

The most common causative organisms include Rhizopus species, Mucor species, and Lichtheimia (formerly known as Absidia). These fungi are saprophytes, meaning they normally feed on dead or decaying organic matter in soil, decomposing vegetation, and compost. However, in certain circumstances, they can become opportunistic pathogens that invade living human tissue.

Understanding the causative organisms 🔗

The fungi responsible for phycomycosis can be divided into two major groups based on their classification and behavior.

Mucorales fungi 🔗

Rhizopus and Mucor are rapidly growing fungi characterized by broad, ribbon-like nonseptate hyphae that branch at right angles. Rhizopus species, particularly Rhizopus oryzae, account for approximately 60% of mucormycosis cases. These organisms are found in various organic substances including mature fruits and vegetables, bread, and soil.

These fungi reproduce through spores contained within structures called sporangia. When cultured in laboratory settings, they produce cotton-candy-like growth that appears white initially and turns grayish-brown as the spores mature. The ability to grow at body temperature (37°C) is what makes certain species particularly dangerous to humans.

Entomophthorales fungi 🔗

A distinct group of fungi causing subcutaneous phycomycosis includes members of the order Entomophthorales, specifically Basidiobolus and Conidiobolus species. These organisms are found in soil, insect droppings, and the intestines of reptiles and amphibians in tropical and subtropical areas. Unlike Mucorales, Entomophthorales typically infect immunocompetent individuals and cause chronic localized infections.

How does infection occur? 🔗

Most cases of mucormycosis are acquired through inhalation of airborne spores. However, the route of infection varies depending on the type of fungus and the clinical presentation. For Mucorales infections, inhalation leads to rhinocerebral or pulmonary disease, while ingestion can cause gastrointestinal disease, and traumatic inoculation through broken skin results in cutaneous infection.

For subcutaneous phycomycosis caused by Entomophthorales, infection is acquired through insect bites or contact with contaminated environments through open skin. This explains why these infections are more common in tropical regions where exposure to insects and environmental fungi is more frequent.

Clinical presentation and progression 🔗

Initial symptoms 🔗

The infection typically begins in the nasal mucosa with early symptoms including unilateral headache, fever, nasal congestion, and facial pain. For subcutaneous forms, patients develop painless, firm subcutaneous nodules that are characteristically non-tender. These nodules may appear on various body parts, particularly the limbs and trunk.

Disease progression 🔗

The hallmark feature of mucormycosis is its aggressive angioinvasive nature. Fungal hyphae invade blood vessel walls, causing thrombosis, tissue infarction, and necrosis. This vascular invasion explains the characteristic black necrotic lesions (eschars) seen in advanced cases, particularly on the nasal mucosa or palate.

When left untreated, rhinocerebral mucormycosis can spread from the sinuses to the orbit and brain. Brain invasion typically occurs through the sphenopalatine and internal maxillary arteries, potentially causing devastating complications including cerebral infarction, meningitis, and brain abscesses.

Who is at risk? 🔗

People are exposed to mucormycete molds every day without getting sick, but immunocompromised individuals face significantly higher risk. The most important risk factors include uncontrolled diabetes mellitus, particularly with diabetic ketoacidosis, hematological malignancies, prolonged corticosteroid therapy, and solid organ or stem cell transplantation.

Patients with diabetes are particularly vulnerable because hyperglycemia suppresses immune function by impairing leukocyte phagocytosis and neutrophil chemotaxis. Additionally, the acidic environment created during ketoacidosis provides favorable conditions for fungal growth. India has reported the highest number of diabetes-related mucormycosis cases globally, partly due to the high prevalence of diabetes and widespread corticosteroid use.

For subcutaneous phycomycosis caused by Entomophthorales, the pattern differs. These infections primarily affect immunocompetent individuals in tropical and subtropical regions, often following minor trauma or insect bites.

Diagnosis and detection 🔗

Early diagnosis is crucial for survival, yet phycomycosis remains challenging to detect in its initial stages. Clinical presentation combined with histopathological evidence or positive culture from infected tissue provides definitive diagnosis. Tissue biopsy reveals the characteristic broad, ribbon-like nonseptate hyphae branching at right angles.

Imaging studies play a vital role in assessing disease extent. Computed tomography scans can reveal sinus opacification and bone erosion, while magnetic resonance imaging better evaluates soft tissue involvement and helps determine the extent of spread to the brain. However, routine blood tests such as beta-D-glucan or Aspergillus galactomannan cannot detect mucormycetes, making tissue diagnosis essential.

Treatment approaches 🔗

Medical management 🔗

Early recognition and prompt administration of appropriate antifungal treatment are critical for improving patient outcomes. Amphotericin B remains the first-line treatment, with lipid formulations preferred due to reduced kidney toxicity. Posaconazole and isavuconazole serve as alternative options for patients who cannot tolerate amphotericin B.

Treatment typically continues for 4 to 6 weeks or longer, depending on disease severity and patient response. Controlling underlying conditions is equally important-diabetic patients require aggressive blood sugar management, and immunosuppressive medications should be reduced or discontinued when possible.

Surgical intervention 🔗

Medical therapy alone is often insufficient. Aggressive surgical debridement of necrotic tissue is essential, particularly for rhinocerebral, cutaneous, and gastrointestinal infections. Surgery removes the infected tissue and fungal mass, reducing the overall fungal burden and improving antifungal drug penetration.

Multiple surgical procedures may be necessary, with the extent of resection depending on disease severity. Endoscopic sinus surgery combined with topical antifungal agents has shown promise for less extensive cases, offering a less invasive approach while maintaining effectiveness.

Prognosis and prevention 🔗

Despite aggressive treatment, mucormycosis carries a high mortality rate. Overall mortality is approximately 50%, though early identification and treatment can lead to better outcomes. The rhinocerebral form has mortality rates ranging from 30% to 70%, while disseminated disease can be fatal in up to 90% of cases.

Prevention focuses on reducing exposure in high-risk individuals. Immunocompromised patients should avoid areas with excessive dust, soil, or decaying organic matter. During natural disasters or construction activities, appropriate masks can reduce spore inhalation. Most importantly, optimal management of underlying conditions-particularly diabetes control-significantly reduces infection risk.

What do you think? How can healthcare facilities better protect immunocompromised patients from environmental fungal exposure? What role should nursing professionals play in early detection of these life-threatening infections?

References

1. https://www.medicinenet.com/mucormycosis/article.htm
2. https://www.cdc.gov/mucormycosis/hcp/clinical-overview/index.html
3. https://microbeonline.com/rhizopus-and-mucor-characteristics-and-diagnosis/
4. https://www.sciencedirect.com/topics/immunology-and-microbiology/rhizopus
5. https://journals.asm.org/doi/abs/10.1128/cmr.00014-18
6. https://www.sciencedirect.com/topics/immunology-and-microbiology/entomophthorales
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088161/
8. https://www.ncbi.nlm.nih.gov/books/NBK559288/
9. https://dermnetnz.org/topics/zygomycosis
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC8484850/